Related Experiment Video
Updated: Dec 18, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
[The RAAS and SARS-CoV-2: A riddle to solve]
M Choi1, E A Aiello1, I L Ennis1
1Sociedad Argentina de Hipertensión Arterial (SAHA), CONICET, CABA, Argentina.
Insights
The renin-angiotensin-aldosterone system (RAAS) inhibitors may be associated with SARS-CoV-2 infection. Further research is needed to understand this evolving topic in COVID-19.
Area of Science:
- Infectious Diseases
- Cardiovascular Pharmacology
Background:
- COVID-19 emerged in late 2019, sparking global health concerns.
- The renin-angiotensin-aldosterone system (RAAS) plays a crucial role in cardiovascular and renal function.
- A potential link between RAAS inhibitors and SARS-CoV-2 infection has been debated.
Purpose of the Study:
- To review current knowledge on the association between RAAS inhibitors and SARS-CoV-2 infection.
- To inform health professionals about the evolving evidence regarding this interaction.
- To consolidate findings from pre-clinical and clinical studies.
Main Methods:
- Review of pre-clinical studies investigating the link between coronavirus and RAAS.
- Analysis of clinical studies examining the association between antihypertensive therapy and SARS-CoV-2 infection.
- Synthesis of existing evidence to provide a current state of knowledge.
Main Results:
- Pre-clinical studies suggest a biological link between the RAAS and coronavirus.
- Clinical evidence on the association between RAAS inhibitors and SARS-CoV-2 infection is still evolving and debated.
- The precise impact of RAAS inhibitors on COVID-19 outcomes requires further investigation.
Conclusions:
- The relationship between RAAS inhibitors and SARS-CoV-2 infection is complex and warrants ongoing research.
- Health professionals should stay updated as new evidence emerges on this topic.
- Further studies are recommended to clarify the clinical implications for patients on RAAS-inhibiting therapies.
Abstract:
The first case of COVID-19 was reported on 31 December 2019 in Wuhan, China. Ever since there has been unprecedented and growing interest in learning about all aspects of this new disease. Debate has been generated as to the association between antihypertensive therapy with renin-angiotensin-aldosterone system (RAAS) inhibitors and SARS-CoV-2 infection. While many questions as yet remain unanswered, the aim of this report is to inform health professionals about the current state of knowledge. Because this is an ever-evolving topic, the recommendation is that it be updated as new evidence becomes available. Below, we provide a review of pre-clinical and clinical studies that link coronavirus to the RAAS.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Viral Recombination
Single Nucleotide Polymorphisms-SNPs
Viruses with RNA Genomes
The JAK-STAT Signaling Pathway

